ArticleBMC cancer2025
Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLung cancer remains the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) have improved survival outcomes for some patients, their efficacy and adverse effects vary significantly. Thus, developing accurate and practical prognostic tools is essential to optimize treatment decision-making.
methodsThis retrospective study analyzed 436 lung cancer patients treated with ICIs, who were randomly divided into training (70%) and validation (30%) cohorts. Independent prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using LASSO regression and multivariate Cox regression. Nomograms were constructed based on clinical and blood biomarkers. Model performance was assessed using the concordance index (C-index), ROC curve, calibration curve, and decision curve analysis (DCA). Kaplan-Meier analysis validated patient stratification.
resultsThe key independent predictive factors for OS and PFS included neutrophil-to-lymphocyte ratio (NLR), previous surgery, liver metastasis, clinical stage, treatment lines, and treatment response evaluation. The nomograms achieved C-index values of 0.709 (OS) and 0.730 (PFS) in the training cohort, with validation C-indexes of 0.655 (OS) and 0.694 (PFS). The ROC curves demonstrated good predictive accuracy for 12-, 24-, and 36-month outcomes. High-risk patients exhibited significantly shorter median OS and PFS (P < 0.001).
conclusionThe nomograms developed in this study, integrating clinical and blood biomarkers, provide a cost-effective, simple, and accurate tool for predicting the prognosis of lung cancer patients receiving ICIs treatment, to facilitate personalized clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.